Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
32.82
-0.43 (-1.29%)
Apr 2, 2026, 9:49 AM EDT - Market open
Collegium Pharmaceutical Revenue
In the year 2025, Collegium Pharmaceutical had annual revenue of $780.57M with 23.62% growth. Collegium Pharmaceutical had revenue of $205.45M in the quarter ending December 31, 2025, with 12.92% growth.
Revenue (ttm)
$780.57M
Revenue Growth
+23.62%
P/S Ratio
1.35
Revenue / Employee
$1,845,312
Employees
423
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 780.57M | 149.12M | 23.62% |
| Dec 31, 2024 | 631.45M | 64.68M | 11.41% |
| Dec 31, 2023 | 566.77M | 102.83M | 22.17% |
| Dec 31, 2022 | 463.93M | 187.07M | 67.56% |
| Dec 31, 2021 | 276.87M | -33.15M | -10.69% |
| Dec 31, 2020 | 310.02M | 13.32M | 4.49% |
| Dec 31, 2019 | 296.70M | 16.29M | 5.81% |
| Dec 31, 2018 | 280.41M | 251.94M | 884.73% |
| Dec 31, 2017 | 28.48M | 26.77M | 1,564.29% |
| Dec 31, 2016 | 1.71M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.25B |
| Evotec SE | 887.40M |
| Tilray Brands | 837.32M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 588.90M |
| Esperion Therapeutics | 403.14M |
| Harrow | 272.30M |
COLL News
- 13 days ago - Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript - Seeking Alpha
- 14 days ago - Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory - GlobeNewsWire
- 21 days ago - Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Collegium to Present New Real-World Data at PainConnect 2026 - GlobeNewsWire
- 4 weeks ago - Collegium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Collegium Pharmaceutical: Buying The Projected Growth For 2026 - Seeking Alpha